European Nuclear Medicine Guide
Radium-223 is indicated for the treatment of adults with castration-resistant prostate cancer who have symptomatic bone metastases with no known visceral metastases and who are in progression after at least two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment.